MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,765.36
-0.47%
NASDAQ 100
$30,725.81
-1.39%
DOW JONES
$51,232.00
+0.10%
NASDAQ Composite
$27,193.34
-1.25%
RUSSELL 2000
$2,775.70
-0.05%
CBOE VIX
$15.41
+2.19%
Sector Heatmap
Technology-1.79%
Financials+0.89%
Healthcare-0.39%
Consumer Cycl+0.31%
Consumer Staples+2.11%
Energy+2.97%
Industrials+0.33%
Materials+0.59%
Real Estate+0.69%
Utilities-0.19%
Comm Services+0.73%
ROIV — Roivant Sciences Ltd. Common Shares
NasdaqRoivant Sciences Ltd. Common Shares
$34.21
-0.54(-1.55%)
- O
- 34.28
- H
- 34.56
- L
- 33.32
- V
- 6.21M
⏱️ End-of-day dataAs of Oct 8, 2026
Chart
About ROIV
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateOct 1, 2021
Employees721
Stock ExchangeNasdaq
Ticker SymbolROIV
Websitehttps://www.roivant.com
Key Financial Statistics
| Market Cap | $25.80B |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $15.90 - $42.50 |
| 52-Week Avg Volume | 6.78M |
| VWAP | $34.05 |
| Transactions | 71,025 |
| Total Recorded Bars | 1,465 days |